Phase I Additional Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Trial Profile

Phase I Additional Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Soft tissue sarcoma; Thyroid cancer
  • Focus Pharmacokinetics
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 09 Nov 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 13 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top